- The report assesses Myocardial Ischemia therapeutics based on drug target, mechanism of action( MoA), route of administration( RoA) and molecule type- The report summarizes all the dormant and discontinued pipeline projects- The report reviews latest news related to pipeline therapeutics for Myocardial Ischemia
Reasons To Buy- Gain strategically significant competitor information, analysis, and insights to formulate effective R & D strategies- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage- Identify and understand important and diverse types of therapeutics under development for Myocardial Ischemia- Identify potential new clients or partners in the target demographic- Develop strategic initiatives by understanding the focus areas of leading companies- Plan mergers and acquisitions effectively by identifying key players and it ' s most promising pipeline therapeutics- Devise corrective measures for pipeline projects by understanding Myocardial Ischemia pipeline depth and focus of Indication therapeutics- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Buy a Sample Copy of This Report @ http:// www. radiantinsights. com / research / myocardial-ischemia-pipelinereview-h2-2016 / request-sample
Table of Contents Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Myocardial Ischemia Overview 8 Therapeutics Development 9 Pipeline Products for Myocardial Ischemia- Overview 9 Pipeline Products for Myocardial Ischemia- Comparative Analysis 10 Myocardial Ischemia- Therapeutics under Development by Companies 11 Myocardial Ischemia- Therapeutics under Investigation by Universities / Institutes 12 Myocardial Ischemia- Pipeline Products Glance 13 Late Stage Products 13 Clinical Stage Products 14 Early Stage Products 15 Myocardial Ischemia- Products under Development by Companies 16 Myocardial Ischemia- Products under Investigation by Universities / Institutes 17 Myocardial Ischemia- Companies Involved in Therapeutics Development 18 Bayer AG 18 Cellmid Limited 19 CohBar, Inc. 20 Lixte Biotechnology Holdings, Inc. 21 Miltenyi Biotec GmbH 22 NoNO, Inc. 23 Shire Plc 24 Symic Biomedical, Inc. 25 Taxus Cardium Pharmaceuticals Group Inc. 26 ViroMed Co., Ltd. 27 Myocardial Ischemia- Therapeutics Assessment 28